Navigation Links
New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
Date:6/24/2014

Singapore, 24 June 2014Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth. The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukaemia immunotherapy .

Leukaemia is characterized by the accumulation of cancer cells originating from blood cells, in the blood or bone marrow. Current treatments for leukaemia largely involve chemotherapy to eradicate all cancer cells, followed by stem cell transplants to restore healthy blood cells in the patients.

In a recent study reported in the Journal of Experimental Medicine (JEM) online, the team co-led by Dr Lucia Mori and Prof Gennaro De Libero identified a new class of lipids, methyl-lysophosphatidic acids (mLPA), which accumulate in leukaemia cells. Following which, the team identified a specific group of immune cells, described as mLPA-specific T-cells that are capable of recognising the mLPA in the leukaemia cells. The detection triggers an immune response that activates the T cells to kill the leukaemia cells and limits cancer progression. The efficacy of the T cells in killing leukaemia cells was also demonstrated in a mouse model of human leukaemia.

Thus far, only proteins in cancer cells have been known to activate T cells. This study is a pioneer in its discovery of mLPA, and the specific T cells which can identify lipids expressed by cancer cells. Unlike proteins, lipids in cancer cells do not differ between individuals, indicating that the recognition of mLPA by mLPA-specific T-cells happens in all leukaemia patients. This new mode of cancer cell recognition suggests that the T-cells can potentially be harnessed for a leukaemia immunotherapy that is effective in all patients.

"The identification of mLPA and its role in activating specific T cells is novel. This knowledge not only sheds light on future leukaemia studies, but also complements ongoing leukaemia immunotherapy studies focusing on proteins in cancer cells," said Dr Lucia Mori, Principal Investigator at SIgN. "Current treatments run the risk of failure due to re-growth of residual leukaemia cells that survive after stem cell transplants. T-cell immunotherapy may serve as a complementary treatment for more effective and safer therapeutic approach towards leukaemia."

Professor Laurent Renia, Acting Executive Director of SIgN, said, "At SIgN, we study how the human immune system protects us naturally from infections. We engage in promising disease-specific research projects that ultimately pave the way for the development of treatments and drugs which can better combat these diseases. A pertinent example will be this study; this mode of immune recognition of leukaemia cells is an insightful discovery that will create new opportunities for immunotherapy to improve the lives of leukaemia patients."


'/>"/>

Contact: Tan Yun Yun
tan_yun_yun@a-star.edu.sg
65-682-66273
Biomedical Sciences Institutes (BMSI)
Source:Eurekalert

Related medicine news :

1. Newly discovered brown fat cells hold possibilities for treating diabetes, obesity
2. Lipids help to fight leukemia
3. Leukemia drug found to stimulate immunity against many cancer types
4. One in 4 children with leukemia not taking maintenance medication, study shows
5. Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
6. Tiny mutation triggers drug resistance for patients with one type of leukemia
7. Major discovery on the mechanism of drug resistance in leukemia and other cancers
8. New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
9. Novel target found for chemotherapy-resistant leukemia cells
10. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
11. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
(Date:1/17/2017)... Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... announced the results of a double blind clinical study for its dental gel that ... a leading national brand of toothpaste containing triclosan. The study was conducted at the ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Today, ... USA Wrestling announced a new agreement as part of a long-term extension of ... 2024 and includes the airing of some of the sport’s premier events exclusively on ...
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff from ... joined other volunteers and organizations in support of the annual Binder Park Zoo Halloween ... dressed up in colorful costumes of all designs coming out to enjoy games, face ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Maureen L. ... announces the addition of 6 senior sales leaders ... TubeClear® System.  These sales leaders were formerly part ... medical device company. Repeatedly recognized for their performance, ... customer expectations and establishing relationships with key customer ...
(Date:1/17/2017)... , January 17, 2017 Transparency Market ... Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market - ... to the report, the global benzaldehyde derivative market was ... reach US$ 2.14 Bn by 2024, expanding at a CAGR of ... ...
(Date:1/16/2017)... -- Research and Markets has announced the addition of ... their offering. ... Global multiple myeloma drugs market to grow at a CAGR of ... the present scenario and the growth prospects of the global multiple ... report considers the revenue generated from the sales of branded and ...
Breaking Medicine Technology: